Serina Therapeutics (Serina Therapeutics) Interest Expense : $-0.30 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Serina Therapeutics's interest expense for the six months ended in Mar. 2024 was $ -0.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.30 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Serina Therapeutics's Operating Income for the six months ended in Mar. 2024 was $ -2.32 Mil. Serina Therapeutics's Interest Expense for the six months ended in Mar. 2024 was $ -0.10 Mil. Serina Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Serina Therapeutics Interest Expense Historical Data

The historical data trend for Serina Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Interest Expense Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Interest Expense

-0.02

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Mar24
Interest Expense	-	-	-0.02	-0.20	-0.10

Serina Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.30 Mil.

Serina Therapeutics (AMEX:SER) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Serina Therapeutics's Interest Expense for the six months ended in Mar. 2024 was $-0.10 Mil. Its Operating Income for the six months ended in Mar. 2024 was $-2.32 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Mar. 2024 was $1.11 Mil.

Serina Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Serina Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

2BO:Germany

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024